SCHEMBL6844179

SCHEMBL6844179

CCCCCCCC(=O)O[C@]12[C@H](C)[C@@H](O)[C@]3(OC(C)=O)[C@H]([C@@H]1C=C(CO)C[C@]1(O)C(=O)C(C)=C[C@@H]21)C3(C)C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 5/20 0.74
PRKCG P05129 5/20 0.74
PRKD3 O94806 4/20 0.74
PRKCB P05771 4/20 0.74
PRKCH P24723 4/20 0.74
PRKCI P41743 4/20 0.74
PRKCE Q02156 4/20 0.74
PRKCQ Q04759 4/20 0.74
PRKCZ Q05513 4/20 0.74
PRKCD Q05655 4/20 0.74
PRKD1 Q15139 4/20 0.74
USP2 O75604 2/20 0.74
TP53 P04637 2/20 0.74
KDM4E B2RXH2 1/20 0.74
ALDH1A1 P00352 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.74
CYP3A4 P08684 1/20 0.74
CYP2C9 P11712 1/20 0.74
TSHR P16473 1/20 0.74
NFKB1 P19838 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9305 1.00 PRKCA (0.74) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL8192421 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL892726 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL18210530 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL21578359 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL22171801 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL2127254 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL16904300 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL312634 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL18627982 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040101932-A1 Compositions and methods for targeted enzymatic release of cell regulatory compounds MARKER GENE TECHNOLOGIES, INC. 2004-05-27 US claimed
EP-1200131-A2 COMPOSITIONS AND METHODS FOR TARGETED ENZYMATIC RELEASE OF CELL REGULATORY COMPOUNDS Marker Gene Technologies, Inc. (US) 2002-05-02 EP claimed
WO-2001002020-A2 COMPOSITIONS AND METHODS FOR TARGETED ENZYMATIC RELEASE OF CELL REGULATORY COMPOUNDS MARKER GENE TECHNOLOGIES, INC. (US) 2001-01-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040101932-A1 Compositions and methods for targeted enzymatic release of cell regulatory compounds GUSB, PREP, PEPD PRKCA 2370/4885PRKCG 1803/4885PRKD3 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.